Kezar Life Sciences (KZR) Rating Increased to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of Kezar Life Sciences (NASDAQ:KZR) from a sell rating to a hold rating in a report published on Thursday.

According to Zacks, “Kezar Life Sciences, Inc. is a bio-technology company. It discovers and develops molecule therapeutics and medicines such as protein homeostasis for autoimmune disorders. The company’s product pipeline consists of KZR-616 which is in clinical stage. Kezar Life Sciences, Inc. is headquartered in South San Francisco, California. “

KZR has been the subject of several other reports. Cowen assumed coverage on Kezar Life Sciences in a research note on Monday, July 16th. They set an outperform rating for the company. Wells Fargo & Co assumed coverage on Kezar Life Sciences in a research note on Monday, July 16th. They set an outperform rating and a $30.00 target price for the company. William Blair assumed coverage on Kezar Life Sciences in a research note on Monday, July 16th. They set an outperform rating for the company. Finally, Jefferies Financial Group assumed coverage on Kezar Life Sciences in a research note on Monday, July 16th. They set a buy rating and a $23.00 target price for the company. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Kezar Life Sciences currently has a consensus rating of Buy and an average target price of $26.50.

NASDAQ:KZR traded up $0.58 during trading hours on Thursday, reaching $24.58. 2,535 shares of the company were exchanged, compared to its average volume of 65,990. Kezar Life Sciences has a 1-year low of $14.77 and a 1-year high of $26.86.

Kezar Life Sciences (NASDAQ:KZR) last issued its quarterly earnings results on Thursday, November 8th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.48) by $0.18. On average, analysts anticipate that Kezar Life Sciences will post -2.64 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in KZR. FMR LLC bought a new stake in Kezar Life Sciences during the second quarter worth $25,995,000. Cowen Inc. bought a new stake in Kezar Life Sciences during the second quarter worth $18,207,000. Frazier Management LLC bought a new stake in Kezar Life Sciences during the second quarter worth $4,325,000. BlackRock Inc. lifted its stake in shares of Kezar Life Sciences by 2,314.5% in the 3rd quarter. BlackRock Inc. now owns 241,446 shares of the company’s stock valued at $5,169,000 after acquiring an additional 231,446 shares during the last quarter. Finally, Acuta Capital Partners LLC bought a new position in shares of Kezar Life Sciences in the 2nd quarter valued at $1,730,000. Hedge funds and other institutional investors own 42.19% of the company’s stock.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Featured Article: Stop Order Uses For Individual Investors

Get a free copy of the Zacks research report on Kezar Life Sciences (KZR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kezar Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kezar Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply